Annual report
4005.TEDINET S100YAUO
Period2025-04-01 → 2026-03-31
Filed2026-06-22
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 153
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.33T | 2025-04-01 → 2026-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥2.61T | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥2.45T | 2023-04-01 → 2024-03-31v | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥2.90T | 2022-04-01 → 2023-03-31v | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥2.77T | 2021-04-01 → 2022-03-31v | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥151.7bn | 2025-04-01 → 2026-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥193.0bn | 2024-04-01 → 2025-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥116.1bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥58.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | −¥462.8bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥231m | 2022-04-01 → 2023-03-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥251.1bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥60.9bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥38.6bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | −¥311.8bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥7.0bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥162.1bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥115.4bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥42.7bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss IFRS |
| Net income | −¥465.4bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss IFRS (5-year summary) |
| Net income | −¥46.9bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥186.4bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss IFRS (5-year summary) |
| Total assets | ¥3.41T | at 2026-03-31 | Cons. | Assets IFRS |
| Total assets | ¥3.44T | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥3.93T | at 2024-03-31v | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥4.17T | at 2023-03-31v | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥4.31T | at 2022-03-31v | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥2.17T | at 2026-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥2.37T | at 2025-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.24T | at 2026-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.07T | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.16T | at 2024-03-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥1.01T | at 2026-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥900.8bn | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥965.8bn | at 2024-03-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥1.17T | at 2023-03-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥1.22T | at 2022-03-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥208.6bn | at 2026-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥209.8bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥217.4bn | at 2024-03-31v | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥305.8bn | at 2023-03-31v | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥365.4bn | at 2022-03-31v | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥234.8bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥233.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | −¥51.3bn | 2023-04-01 → 2024-03-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥111.6bn | 2022-04-01 → 2023-03-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥171.7bn | 2021-04-01 → 2022-03-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥74.8bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | ¥85.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥112.2bn | 2023-04-01 → 2024-03-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥19.4bn | 2022-04-01 → 2023-03-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥115.4bn | 2021-04-01 → 2022-03-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥199.1bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥300.8bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥49.2bn | 2023-04-01 → 2024-03-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥178.5bn | 2022-04-01 → 2023-03-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥81.4bn | 2021-04-01 → 2022-03-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥37.16 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥23.59 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥-190.69 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥4.27 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥99.16 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥37.15 | 2025-04-01 → 2026-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥23.58 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥4.27 | 2022-04-01 → 2023-03-31v | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥610.78 | at 2026-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥550.37 | at 2025-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥590.44 | at 2024-03-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥716.26 | at 2023-03-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥745.03 | at 2022-03-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 29.6% | at 2026-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 26.2% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 24.5% | at 2024-03-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 28.1% | at 2023-03-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 28.3% | at 2022-03-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 6.4% | 2025-04-01 → 2026-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 4.1% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | -29.2% | 2023-04-01 → 2024-03-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 0.6% | 2022-04-01 → 2023-03-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 14.5% | 2021-04-01 → 2022-03-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 27,491 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 29,279 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 32,161 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 33,572 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 34,703 | at 2022-03-31v | Cons. | Number of employees |
| Revenue | ¥758.2bn | 2025-04-01 → 2026-03-31 | Standalone | Net sales |
| Revenue | ¥856.6bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥809.6bn | 2023-04-01 → 2024-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥894.4bn | 2022-04-01 → 2023-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥797.4bn | 2021-04-01 → 2022-03-31v | Standalone | Net sales (5-year summary) |
| Operating income | ¥35.2bn | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | ¥59.7bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | ¥60.0bn | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥84.9bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥53.4bn | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥69.5bn | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥68.5bn | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥29.3bn | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥42.9bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | ¥32.1bn | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | ¥24.2bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥8.7bn | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥50.4bn | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥61.7bn | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥1.70T | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥1.82T | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥1.90T | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.77T | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.74T | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥1.28T | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥1.42T | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥421.6bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥393.9bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥370.4bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥378.0bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥368.8bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥23.8bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥85.7bn | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥19.57 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥14.77 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥5.32 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥30.85 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥37.76 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥13.5 | 2025-04-01 → 2026-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥9 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥9 | 2023-04-01 → 2024-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥18 | 2022-04-01 → 2023-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥24 | 2021-04-01 → 2022-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥255.28 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥240.68 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥226.42 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥231.14 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥225.56 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 24.8% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 21.7% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 19.5% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 21.3% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 21.2% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 7.9% | 2025-04-01 → 2026-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.3% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.3% | 2023-04-01 → 2024-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 13.5% | 2022-04-01 → 2023-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 17.3% | 2021-04-01 → 2022-03-31v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 1,657,914,000 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,657,217,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,656,449,000 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,655,860,000 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,655,446,000 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 6,465 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 6,669 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 6,706 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 6,637 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 6,488 | at 2022-03-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 104
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2025-04-01 → 2026-03-31 | ¥7.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2026-03-31 | 1305 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-04-01 → 2026-03-31 | ¥94.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-04-01 → 2026-03-31 | ¥45.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥49.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2026-03-31 | ¥231.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-04-01 → 2026-03-31 | ¥4.4bn |
| Reconciling Itemsreconciling | capex | 2025-04-01 → 2026-03-31 | ¥9.6bn |
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2026-03-31 | −¥70.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2026-03-31 | −¥70.8bn |
| Reconciling Itemsreconciling | segment assets | at 2026-03-31 | ¥80.9bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2026-03-31 | −¥31.1bn |
| Advanced Medical Solutionsreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥9.6bn |
| Advanced Medical Solutionsreportable segment | employees | at 2026-03-31 | 2161 pure |
| Advanced Medical Solutionsreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥72.4bn |
| Advanced Medical Solutionsreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥58.6bn |
| Advanced Medical Solutionsreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥13.8bn |
| Advanced Medical Solutionsreportable segment | segment assets | at 2026-03-31 | ¥125.2bn |
| Advanced Medical Solutionsreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥2.8bn |
| Agro And Life Solutionsreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥15.8bn |
| Agro And Life Solutionsreportable segment | employees | at 2026-03-31 | 7016 pure |
| Agro And Life Solutionsreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥520.4bn |
| Agro And Life Solutionsreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥519.3bn |
| Agro And Life Solutionsreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥1.1bn |
| Agro And Life Solutionsreportable segment | segment assets | at 2026-03-31 | ¥819.6bn |
| Agro And Life Solutionsreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥56.3bn |
| Essential And Green Materialsreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥18.2bn |
| Essential And Green Materialsreportable segment | employees | at 2026-03-31 | 3030 pure |
| Essential And Green Materialsreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥683.4bn |
| Essential And Green Materialsreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥678.8bn |
| Essential And Green Materialsreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥4.6bn |
| Essential And Green Materialsreportable segment | segment assets | at 2026-03-31 | ¥639.9bn |
| Essential And Green Materialsreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥14.4bn |
| ICT And Mobility Solutionsreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥53.0bn |
| ICT And Mobility Solutionsreportable segment | employees | at 2026-03-31 | 9563 pure |
| ICT And Mobility Solutionsreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥575.1bn |
| ICT And Mobility Solutionsreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥574.2bn |
| ICT And Mobility Solutionsreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥968m |
| ICT And Mobility Solutionsreportable segment | segment assets | at 2026-03-31 | ¥722.6bn |
| ICT And Mobility Solutionsreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥53.0bn |
| Sumitomo Pharmareportable segment | capex | 2025-04-01 → 2026-03-31 | ¥8.1bn |
| Sumitomo Pharmareportable segment | employees | at 2026-03-31 | 3112 pure |
| Sumitomo Pharmareportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥453.3bn |
| Sumitomo Pharmareportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥451.9bn |
| Sumitomo Pharmareportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥1.4bn |
| Sumitomo Pharmareportable segment | segment assets | at 2026-03-31 | ¥785.9bn |
| Sumitomo Pharmareportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥108.4bn |
| —segment total | capex | 2025-04-01 → 2026-03-31 | ¥104.7bn |
| —segment total | revenue | 2025-04-01 → 2026-03-31 | ¥2.30T |
| —segment total | revenue external | 2025-04-01 → 2026-03-31 | ¥2.28T |
| —segment total | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥21.8bn |
| —segment total | segment assets | at 2026-03-31 | ¥3.09T |
| —segment total | segment profit | 2025-04-01 → 2026-03-31 | ¥235.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2024-04-01 → 2025-03-31 | ¥4.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2025-03-31 | ¥165.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2025-03-31 | ¥99.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥65.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2025-03-31 | ¥284.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2025-03-31 | ¥66.9bn |
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥7.2bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥85.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥85.4bn |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥102.2bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥32.7bn |
| Advanced Medical Solutionsreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥13.0bn |
| Advanced Medical Solutionsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥72.5bn |
| Advanced Medical Solutionsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥62.1bn |
| Advanced Medical Solutionsreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥10.4bn |
| Advanced Medical Solutionsreportable segment | segment assets | at 2025-03-31 | ¥125.3bn |
| Advanced Medical Solutionsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥4.0bn |
| Agro And Life Solutionsreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥20.1bn |
| Agro And Life Solutionsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥541.3bn |
| Agro And Life Solutionsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥540.2bn |
| Agro And Life Solutionsreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥1.1bn |
| Agro And Life Solutionsreportable segment | segment assets | at 2025-03-31 | ¥771.3bn |
| Agro And Life Solutionsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥55.0bn |
| Essential And Green Materialsreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥26.3bn |
| Essential And Green Materialsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥903.9bn |
| Essential And Green Materialsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥899.0bn |
| Essential And Green Materialsreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥4.9bn |
| Essential And Green Materialsreportable segment | segment assets | at 2025-03-31 | ¥791.9bn |
| Essential And Green Materialsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | −¥58.5bn |
| ICT And Mobility Solutionsreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥49.2bn |
| ICT And Mobility Solutionsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥610.3bn |
| ICT And Mobility Solutionsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥607.0bn |
| ICT And Mobility Solutionsreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥3.3bn |
| ICT And Mobility Solutionsreportable segment | segment assets | at 2025-03-31 | ¥635.7bn |
| ICT And Mobility Solutionsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥70.6bn |
| Sumitomo Pharmareportable segment | capex | 2024-04-01 → 2025-03-31 | ¥11.5bn |
| Sumitomo Pharmareportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥398.5bn |
| Sumitomo Pharmareportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥398.0bn |
| Sumitomo Pharmareportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥529m |
| Sumitomo Pharmareportable segment | segment assets | at 2025-03-31 | ¥728.7bn |
| Sumitomo Pharmareportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥35.3bn |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥120.1bn |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥2.53T |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥2.51T |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥20.2bn |
| —segment total | segment assets | at 2025-03-31 | ¥3.05T |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥106.4bn |
| Advanced Medical Solutionsreportable segment | employees | at 2026-03-31 | 648 pure |
| Agro And Life Solutionsreportable segment | employees | at 2026-03-31 | 1445 pure |
| Essential And Green Materialsreportable segment | employees | at 2026-03-31 | 1374 pure |
| ICT And Mobility Solutionsreportable segment | employees | at 2026-03-31 | 1862 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,628
| Item | Context | Value | Unit |
|---|---|---|---|
| Price earnings ratio (5-year summary) | Prior4YearDuration_NonConsolidatedMember | 14.88 | |
| Price earnings ratio (5-year summary) | Prior3YearDuration_NonConsolidatedMember | 14.42 | |
| Price earnings ratio (5-year summary) | Prior2YearDuration_NonConsolidatedMember | 63.65 | |
| Price earnings ratio (5-year summary) | Prior1YearDuration_NonConsolidatedMember | 24.47 | |
| Price earnings ratio (5-year summary) | CurrentYearDuration_NonConsolidatedMember | 25.52 | |
| Payout ratio (5-year summary) | Prior4YearDuration_NonConsolidatedMember | 0.636 | |
| Payout ratio (5-year summary) | Prior3YearDuration_NonConsolidatedMember | 0.584 | |
| Payout ratio (5-year summary) | Prior2YearDuration_NonConsolidatedMember | 1.691 | |
| Payout ratio (5-year summary) | Prior1YearDuration_NonConsolidatedMember | 0.609 | |
| Payout ratio (5-year summary) | CurrentYearDuration_NonConsolidatedMember | 0.690 | |
| Number of employees | Prior4YearInstant_NonConsolidatedMember | 6488 | |
| Number of employees | Prior3YearInstant_NonConsolidatedMember | 6637 | |
| Number of employees | Prior2YearInstant_NonConsolidatedMember | 6706 | |
| Number of employees | Prior1YearInstant_NonConsolidatedMember | 6669 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 6465 | |
| Average number of temporary workers | Prior4YearInstant_NonConsolidatedMember | 341 | |
| Average number of temporary workers | Prior3YearInstant_NonConsolidatedMember | 381 | |
| Average number of temporary workers | Prior2YearInstant_NonConsolidatedMember | 419 | |
| Average number of temporary workers | Prior1YearInstant_NonConsolidatedMember | 434 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 422 | |
| Total shareholder return | Prior4YearInstant_NonConsolidatedMember | 1.023 | |
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | 0.850 | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 0.680 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 0.735 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 1.000 | |
| Total return on share price index | Prior4YearInstant_NonConsolidatedMember | 1.020 | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | 1.079 | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 1.525 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 1.502 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 2.022 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | 15 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | 16.3 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row3Member | 100 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row3Member | 81.5 | |
| Research and development expenses research and development activities | CurrentYearDuration | 144700000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E00752-000AgroAndLifeSolutionsReportableSegmentMember | 31600000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E00752-000ICTAndMobilitySolutionsReportableSegmentMember | 33400000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E00752-000AdvancedMedicalSolutionsReportableSegmentMember | 3800000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E00752-000EssentialAndGreenMaterialsReportableSegmentMember | 8400000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E00752-000SumitomoPharmaReportableSegmentMember | 44000000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_CorporateSharedMember | 23500000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E00752-000AgroAndLifeSolutionsReportableSegmentMember | 15846000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E00752-000ICTAndMobilitySolutionsReportableSegmentMember | 52970000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E00752-000AdvancedMedicalSolutionsReportableSegmentMember | 9575000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E00752-000EssentialAndGreenMaterialsReportableSegmentMember | 18176000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E00752-000SumitomoPharmaReportableSegmentMember | 8115000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 7261000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_CorporateSharedMember | 9617000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 121560000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 1657914399 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |